Gene:
KRT83
keratin 83

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  hard keratin type II
Alternate Symbols:  Hb-3
PharmGKB Accession Id: PA30249

Details

Cytogenetic Location: chr12 : q13.13 - q13.13
GP mRNA Boundary: chr12 : 52708085 - 52715182
GP Gene Boundary: chr12 : 52705085 - 52725182
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to KRT83: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature genetics. 2003. Cheok Meyling H, et al. PubMed

LinkOuts

Entrez Gene:
3889
OMIM:
158000
602765
UCSC Genome Browser:
NM_002282
RefSeq RNA:
NM_002282
RefSeq Protein:
NP_002273
RefSeq DNA:
AC_000144
NC_000012
NG_008352
NT_029419
NW_001838058
NW_921705
NW_925352
UniProtKB:
KRT83_HUMAN (P78385)
Ensembl:
ENSG00000170523
GenAtlas:
KRT83
GeneCard:
KRT83
MutDB:
KRT83
ALFRED:
LO045945B
HuGE:
KRT83
Comparative Toxicogenomics Database:
3889
ModBase:
P78385
HumanCyc Gene:
HS10143
HGNC:
6460

Common Searches